Neurocrine Biosciences stock
NBIXNASDAQNeurocrine Biosciences, Inc., HealthcareISIN US64125C1099
77Score 77 out of 100, Strong
Price and trend
68 / 100
Price history
+15% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 14% above it.
Since October 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Overheated: the price has risen very quickly lately (RSI 76).
The price is 8.7% below its 52-week high. Largest decline in 20 years: 86% (February 2007 to November 2009).
Chart figures for advanced users
- SMA 50$148.40
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$148.73
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)76
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$123.10
- The lowest closing price of the last twelve months.
- Resistance$185.50
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Neurocrine Biosciences, Inc. belongs to the Biotechnology industry (United States) and, with a market value of $17.15B, is number 22 of 289 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $2.86B (up 21.4% year on year) and earnings of $478.6M (up 40.2%).
- For fiscal 2026, analysts expect on average revenue of $3.99B (up 39.4%) and adjusted earnings per share of $7.33 (up 44.8%).
Show more
- MEQIRI Score 77 out of 100 (Strong): rank 42 of 702 in Healthcare, median 53.
- The P/E is 25.4 (Biotechnology median 21.7, own median of recent years 45.8).
- Our model puts fair value at $183.45, with the price 8% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Earnings turn into cashFree cash flow 148% of earnings over the last 12 months.Fundamentals 84
- More cash than debtCash $737.9M, financial debt $392.3M.Stability 87
- Analysts expect strong earnings growthUp 21.1% a year through 2028 (estimates from 19 analysts).Growth 86
Weaknesses
None of our weakness checks flags anything. Crash risk is measured separately.
Its standout strengths are stability and growth.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Fundamentals are strong, with stable profits and strong cash generation.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk medium
How well MEQIRI warnsIn the middle among stocks ranked 101 to 1,000.
From 2016 to 2025, 13 in 100 such stocks fell 30% or more within a year, against a group average of 15 in 100.
What drives the risk
- high growth grade (crashed more often in the backtest)
What lowers it
- solid fundamentals
- price near its 52-week high
Valuation
Valuation signal
Fairly valuedIn our model the price counts as cheap below $141.12 and expensive above $262.07 (uncertainty medium, based on the price swings of the past year).
The two parts of the fair value come to $221.86 (cash-flow model) and $145.04 (industry comparison), and the gap between them shows how uncertain the estimate is.
Calculated with a cost of equity of 9.3%. At 10.3% the fair value would be $167.06, at 8.3% it would be $207.07.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (21.7).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 38% on the twelve months before. Revenue has grown strongly since 2015, at around 64% per year. From 2015 revenue is reported differently (for example gross instead of net), so earlier years are not comparable and not shown.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 98%, operating 22%, net 17%. From 2015 revenue is reported differently (for example gross instead of net), so earlier years are not comparable and not shown.
Debt & balance sheet
latest quarterThe balance sheet is solid, with low debt and comfortable interest coverage.
Earnings
- Next earnings
- 10 Feb 2027in 89 days
- Last reported
- 2 Nov 2026EPS reported $3.29 (expected $1.91)above expectations
Analyst estimates
Analysts have raised their 2026 earnings estimate by 3.9% since 15 Oct 2026.
- Earnings per share
- $7.33+3.9%
- Revenue
- $3.99B+2.2%
- Earnings per share
- $9.75+0.4%
- Revenue
- $4.57B+1.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: −7.7%2026 Ingrezza revenue guidance raised to $2.825 billion to $2.875 billion (from $2.7 billion to $2.8 billion), about 13% growth at the midpoint.
“Given this performance, we are raising our full-year INGREZZA guidance from $2.7 billion to $2.8 billion to a new range of $2.825 billion to $2.875 billion At the midpoint, this represents approximately 13% year over year growth.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 30 Jul 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 12 insiders sold, $65.02M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Morrow George JSale
3 Nov 2026, Board
- Shares
- 7,200
- Price
- $166.37
- Value
- $1.2M
- Morrow George JSale
2 Nov 2026, Board
- Shares
- 7,500
- Price
- $145.79
- Value
- $1.09M
- Morrow George JSale
30 Oct 2026, Board
- Shares
- 300
- Price
- $149.00
- Value
- $44,700
Show 20 more
- Boyer David W.Sale
14 Sept 2026, Chief Corp. Affairs Officer
- Shares
- 826
- Price
- $157.45
- Value
- $130,051
- Abernethy MattSale
14 Sept 2026, Chief Financial Officer
- Shares
- 2,311
- Price
- $157.20
- Value
- $363,285
- Benevich EricSale
9 Sept 2026, Chief Commercial Officer
- Shares
- 2,154
- Price
- $154.61
- Value
- $333,030
- Norwalk Leslie VSale
28 Jul 2026, Board
- Shares
- 1,250
- Price
- $182.01
- Value
- $227,508
- Delaet IngridSale
10 Jul 2026, Chief Regulatory Officer
- Shares
- 4,367
- Price
- $181.02
- Value
- $790,514
- Lippoldt DarinSale
9 Jul 2026, Chief Legal Officer
- Shares
- 10,000
- Price
- $179.60
- Value
- $1.8M
- Delaet IngridSale
9 Jul 2026, Chief Regulatory Officer
- Shares
- 8,433
- Price
- $178.72
- Value
- $1.51M
- Delaet IngridSale
8 Jul 2026, Chief Regulatory Officer
- Shares
- 2,737
- Price
- $178.54
- Value
- $488,672
- Delaet IngridSale
7 Jul 2026, Chief Regulatory Officer
- Shares
- 3,401
- Price
- $178.57
- Value
- $607,305
- Lippoldt DarinSale
29 Jun 2026, Chief Legal Officer
- Shares
- 9,800
- Price
- $170.16
- Value
- $1.67M
- Lippoldt DarinSale
26 Jun 2026, Chief Legal Officer
- Shares
- 200
- Price
- $169.57
- Value
- $33,913
- Sherwin Stephen ASale
5 Jun 2026, Board
- Shares
- 25,000
- Price
- $165.32
- Value
- $4.13M
- Norwalk Leslie VSale
4 Jun 2026, Board
- Shares
- 1,250
- Price
- $168.06
- Value
- $210,072
- Cooke JulieSale
2 Jun 2026, Chief Human Resources Officer
- Shares
- 36,937
- Price
- $156.22
- Value
- $5.77M
- Onyia JudeSale
1 Jun 2026, Chief Scientific Officer
- Shares
- 11,000
- Price
- $160.25
- Value
- $1.76M
- Delaet IngridSale
29 May 2026, Chief Regulatory Officer
- Shares
- 2,261
- Price
- $156.71
- Value
- $354,321
- Onyia JudeSale
27 May 2026, Chief Scientific Officer
- Shares
- 11,000
- Price
- $155.53
- Value
- $1.71M
- Boyer David W.Sale
26 May 2026, Chief Corp. Affairs Officer
- Shares
- 3,888
- Price
- $156.64
- Value
- $609,023
- Gorman Kevin CharlesSale
19 May 2026, Board
- Shares
- 245,088
- Price
- $154.33
- Value
- $37.82M
- Pops Richard FSale
15 May 2026, Board
- Shares
- 15,000
- Price
- $157.65
- Value
- $2.36M
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Neurocrine Biosciences
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 77
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- BioNTechBNTX $20.98B36
- Innovent Biologics1801.HK $19.28B61
- Ascendis PharmaASND $17.57B69
- ExelixisEXEL $17.55B90
- Jazz PharmaceuticalsJAZZ $15.43B66
- BridgeBio PharmaBBIO $15.23B49
- Sichuan Kelun-Biotech Biopharmaceutical6990.HK $13.9B49
- Kymera TherapeuticsKYMR $12.73B45
ETFs that hold Neurocrine Biosciences
Held by 73 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares Healthcare Innovation UCITS ETF2B78 | 1.14% | 0.40% | €1.5B |
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 1.07% | 0.35% | €1.25B |
| Invesco NASDAQ Next Generation 100 UCITS ETF AccEQQJ | 0.87% | 0.25% | €45.16M |
Show 5 more
| iShares Ageing Population UCITS ETF2B77 | 0.49% | 0.40% | €813.42M |
| State Street SPDR S&P 400 U.S. Mid Cap UCITS ETF (Acc)SPY4 | 0.48% | 0.30% | €5.36B |
| iShares Edge MSCI USA Minimum Volatility Advanced UCITS ETFMVEA | 0.45% | 0.20% | €119.49M |
| iShares MSCI USA Mid-Cap Equal Weight UCITS ETFQDVC | 0.35% | 0.20% | €272.21M |
| iShares Edge MSCI World Minimum Volatility UCITS ETF USD (Dist)UEEH | 0.32% | 0.30% | €12.86M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 1 May 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.